Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CREBBP | Q92793 | 1/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6108649 | 1.00 | CREBBP (0.33) | CREBBPDPP7NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6108396 | 0.93 | SMN1; SMN2 (0.36) | CREBBPNPC1RAB9ASMN1; SMN2MCL1 | |
| SCHEMBL6108399 | 0.93 | SMN1; SMN2 (0.36) | CREBBPNPC1RAB9ASMN1; SMN2MCL1 | |
| SCHEMBL6108395 | 0.93 | SMN1; SMN2 (0.36) | CREBBPNPC1RAB9ASMN1; SMN2MCL1 | |
| SCHEMBL6106325 | 0.89 | RIPK1 (0.30) | — | |
| SCHEMBL6106331 | 0.89 | RIPK1 (0.30) | — | |
| SCHEMBL6106457 | 0.86 | SMN1; SMN2 (0.36) | CREBBPNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6106465 | 0.86 | SMN1; SMN2 (0.36) | CREBBPNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6106460 | 0.86 | SMN1; SMN2 (0.36) | CREBBPNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6106289 | 0.84 | CREBBP (0.34) | CREBBPMCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7135484-B2 | Azabicyclic compounds are central nervous system active agents | ABBOTT LABORATORIES (US) | 2006-11-14 | — | — | US | disclosed |
| US-20040152724-A1 | Azabicyclic compounds are central nervous system active agents | ABBVIE INC. | 2004-08-05 | — | — | US | disclosed |
| US-20040044029-A1 | Azabicyclic compounds are central nervous system active agents | ABBOTT LABORATORIES | 2004-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152724-A1 | Azabicyclic compounds are central nervous system active agents | ACHE, CHRNA6, CHRNA2 | CREBBP 935/4885DPP7 3383/4885NPC1 654/4885 |
| US-20040044029-A1 | Azabicyclic compounds are central nervous system active agents | ACHE, CHRNA6, CHRNA2 | CREBBP 935/4885DPP7 3383/4885NPC1 654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.